Technology
Health
Medical

Apollo Endosurgery

$3.68
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.25 (7.42%) Today
+$0.06 (1.66%) After Hours

Why Robinhood?

You can buy or sell APEN and other stocks, options, ETFs, and crypto commission-free!

About

Apollo Endosurgery, Inc. Common Stock, also called Apollo Endosurgery, is a medical technology company, which engages in the design, development, and commercialization of medical devices. Read More It offers medical devices for bariatric and gastrointestinal procedures under the ORBERA and OverStitch brands. The company was founded by Christopher J. Gostout in 2006 and is headquartered in Austin, TX.

Employees
213
Headquarters
Austin, Texas
Founded
2006
Market Cap
73.78M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
49.14K
High Today
$3.64
Low Today
$3.34
Open Price
$3.35
Volume
5.84K
52 Week High
$9.65
52 Week Low
$3.02

Collections

Technology
Health
Medical
Medical Devices
US
North America

News

Seeking AlphaMar 18

Apollo Endosurgery, Inc. (APEN) CEO Todd Newton on Q4 2018 Results - Earnings Call Transcript

Apollo Endosurgery, Inc. (NASDAQ:APEN) Q4 2018 Earnings Conference Call March 18, 2019 8:30 AM ET Company Participants John Gillings - Investor Relations Todd Newton - Chief Executive Officer Stefanie Cavanaugh - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig Hallum JP McKim - Piper Jaffray Suraj Kalia - Northland Securities Operator Good morning, my name is Sharon, and I will be your conference operator today. At this time, I would like to welcome everyone to the Apollo ...

10
MarketBeatFeb 23

Stock Price, News, & Analysis for Apollo Endosurgery

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. It develops and distributes devices for minimally invasive surgical and non-surgical bariatric and gastrointestinal procedures that are used by surgeons and gastroenterologists in various settings to provide interventional therapy to patients who suffer from obesity and various co-morbidities associated with obesity, as well as treat various other gastrointestinal conditions....

6

Earnings

-$0.64
-$0.53
-$0.43
-$0.32
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.37 per share
Actual
-$0.48 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.